Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Bullboard Posts
Comment by Sonny7on Apr 10, 2015 3:23am
172 Views
Post# 23615561

RE:RE:Ventripoint Response to Interactive Review for Recent 510(k)

RE:RE:Ventripoint Response to Interactive Review for Recent 510(k)I believe that VMS - VPT does have FDA attention this time. It's my understanding that on the initial application the reviewer(s) made errors in their interpretation of the test and rejected the application without review. With that announcement, Dr Adams released news of an appeal on the FDA decision. I think of FDA as being corrupt and arrogant so the business of an appeal would be undesirable to them when the test actually had passing grades. In a face saving gesture they altered the trials name and approved it, "hand delivering it to Dr Adams" when approved. So yes, I think they now have FDA "owing them one", so to speak. That said, I believe FDA will fast track this submission and it's my belief that good news will prevail sooner than later. 

In my opinion 
Bullboard Posts